RxDoctor Payments Data

Allan Martin, MD

General Practice · Salem, NJNPI 1679696843

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 59 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$291
  • Teva Pharmaceuticals USA, Inc.$248
  • Braeburn Inc.$142
  • AbbVie$48
  • Urovant Sciences Inc$40
  • Sunovion Pharmaceuticals Inc.$38
  • plus $218 from 10 others

What the payments were for

  • Food & beverage$84683%
  • Education$17817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,024 in reported general payments places this provider in the 85th percentile of 2,978 general practice providers in New Jersey.

See all general practice providers in New Jersey

Medicare billing

Part B allowed, 2024
$11,220
Medicare patients
37
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide96$53,830
SuboxoneBuprenorphine Hcl/Naloxone Hcl49$47,576
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl262$43,290
ProliaDenosumab16$29,517
ZubsolvBuprenorphine Hcl/Naloxone Hcl27$23,893
FycompaPerampanel12$15,154
XcopriCenobamate12$14,643
AptiomEslicarbazepine Acetate11$14,454
EliquisApixaban19$7,966
MovantikNaloxegol Oxalate13$5,282
Repatha SyringeEvolocumab14$4,960
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,135
Esomeprazole Magnesium54$3,914
Divalproex Sodium ErDivalproex Sodium48$3,483
Levetiracetam91$3,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$48$53,83096 claims
Orexo US, Inc.Zubsolv$291$23,89327 claims
SK Life Science, Inc.Xcopri$30$14,64312 claims
Sunovion Pharmaceuticals Inc.Aptiom$38$14,45411 claims
PfizerEliquis$27$7,96619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,978 general practice providers in New Jersey.

Other general practice in Salem

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →